Instructions for Authors 2021

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis; 10. Retrospective studies and case reports. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. IN VIVO provides for the prompt online publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 800.00 (effective January 1, 2021) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion.

Figures (graphs and photographs). All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. The number of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN Vivo agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html. In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for peer-review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
- Results given in figures should not be repeated in tables.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

8. Articles submitted to IN VIVO may be rejected without review if:

- they do not fall within the journal’s policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to IV.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2020): 64%).

9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

11. Authors who wish to organize or edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

Copyright© 2021 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Selection of Recent Articles

The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Y.M. MORILLON II, A. SABZEVARI, J. SCHLOM, J.W. GREINER (Bethesda, MD, USA)

Human NK-92 Cells Function as Target Cells for Human NK Cells – Implications for CAR NK-92 Therapies. H. BERGMAN, N. SISSALA, H. HÄGERSTRAND, C. LINQVIST (Turku, Finland)


Expression of ATP-binding Cassette Transporter 11 (ABCC11) Protein in Colon Cancer. Y. YAMADA, K. YOSHIMATSU, H. YOKOMIZO, S. OKAYAMA, S. SHIOZAWA (Tokyo, Japan)

Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway. C. KOENIGSBERG, F.G. ONDREY (Minneapolis, MN, USA)

Presence of the Transmembrane Protein Neutropilin in Cytokine-induced Killer Cells. E.V. DÍEZ GARCÍA DE OLALLA, F. GAROFANO, H. WEIHER, M. MUDERS, S. FÖRSTER, I.G.H. SCHMIDT-WOLF (Bonn; Rheinbach, Germany)


WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer. S. LEE, J. JUN, W.J. KIM, P. TAMAYO, S.B. HOWELL (Seoul, Republic of Korea; San Diego, CA, USA)

Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment. S.Y. LEE, B. SLAGLE-WEBB, A.K. SHARMA, J.R. CONNOR (Hershey, PA, USA)

An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma. K.J.V. DAHLQUIST, L.C. VOTH, A.J. FEE, A.K. STOECKMAN (Saint Paul, MN, USA)

Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC. R. BIRK, A. SCHELL, C. ADERHOLD, H. SOCHO, L. HUBER, C.E. MUELLER, A. LAMMERT, C. SCHERL, N. ROTTER, J.U. SOMMER, B. KRAMER (Marburg; Mannheim; Wuppertal, Germany)


Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer. H. MINAMI, Y. ANDO, K. TAMURA, T. TAJIMA, R. ISAACS (Kobe; Nagoya; Tokyo, Japan; East Hanover, NJ, USA)
General Policy

- **CANCER GENOMICS & PROTEOMICS** (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

- CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

- **U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- **E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

---

**Selection of Recent Articles**


- Stem-like Cells from Invasive Breast Carcinoma Cell Line MDA-MB-231 Express a Distinct Set of Eph Receptors and Ephrin Ligands. M. LUCERO, J. THIND, J. SANDOVAL, S. SENAATI, B. JIMENEZ, R.P. KANDPAL (Pomona, CA, USA)

- Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. A. RIZZO, A.D. RICCI, S. TAVOLARI, G. BRANDI (Bologna, Italy)

- Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase. E. MAZZIO, R. BADISA, N. MACK, S. CASSIM, M. ZDRALEVIC, J. POUYSSEGUR, K.F.A. SOLIMAN (Tallahassee, FL, USA; Monaco; Monaco; Nice, France)

- TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer. M. IDRISSEU, T. BOISNIER, A. SANCHEZ, F.Z.H. KOHOUAF, F. PENAULT-LLORCA, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)

- STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer. S. NAKAMURA, M. KANDA, D. SHIMIZU, K. SAWAKI, C. TANAKA, N. HATTORI, M. HAYASHI, S. YAMADA, G. NAKAYAMA, K. OMAE, M. KOIKE, Y. KODERA (Nagoya; Fukushima, Japan)

- Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV− Squamous Cell Carcinoma. B. KANSY, C. ADERHOLD, L. HUBER, S. LUDWIG, R. BIRK, A. LAMMERT, S. LANG, N. ROTTER, B. KRAMER (Essen; Mannheim; Marburg, Germany)

- Chromobox2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. S. UEDA, M. KANDA, Y. SATO, H. BABA, S. NAKAMURA, K. SAWAKI, D. SHIMIZU, S. MOOTOYAMA, T. FUJII, Y. KODERA, S. NOMOTO (Nagoya; Akita; Toyama, Japan)

- Fusion of the Lumican (*LUM*) Gene With the Ubiquitin Specific Peptidase 6 (*USP6*) Gene in an Aneurysmal Bone Cyst Carrying a *t(12;17)(q21;p13)* Chromosome Translocation. I. PANAGÓPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, M. LUND-IVERSEN, F. MICCI, S. HEIM (Oslo, Norway)

- Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. M. CHEVALLIER, P. TSANTOULIS, A. ADDEO, A. FRIELAENDER (Geneva, Switzerland)

- Long Noncoding RNA *ANROC* on the *INK4* Locus Functions to Suppress Cell Proliferation. Y. KOTAKE, T. TSURUDA (Fukuoka, Japan)


Periprosthetic Fracture Resembling Atypical Femoral Fracture After Fixation With Retrograde Intramedullary Nail in Elderly Women: A Report of Two Cases. Y. TAKAHASHI, S. HATASHITA, Y. SHINDEN, M. ITO, Y. KANEUCHI, M. HAKOZAKI, S. KONNO (Fukushima, Japan) .............................. 1837

Assessment of Blood Plasma Free-amino Acid Levels in Infertile Men. T. SUGIYAMA, H. TERADA, H. MIYAKE (Hamamatsu, Japan) ............................................................................................................. 1843


A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation. Y.-S. KAO, Y. HSU (Taichung; Changhua, Taiwan, ROC) ............................................................................................................. 1857


Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops. F. DI STASO, I. GATTAZZO, B.T. SALIMBENI, A. LAMBIASE, G. SCUDERI, S. DI STASO, M. CIANCAGLINI (Rome; L’Aquila, Italy) ............................................................................................................. 1881

Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and Cyclophosphamide. S. JALALI, D. JENNEMAN, A. TANDON, H. KHONG (Tampa, FL, USA) ............................................................................................................. 1885

Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. H. IWAMOTO, H. KANO, T. SHIMADA, R. NAITO, T. MAKINO, S. KADOMOTO, H. YAEGLASHI, K. SHIGEHARA, K. IZUMI, Y. KADON, A. MIZOKAMI (Kanazawa, Japan) .......................................................... 1703

Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey. R.E. FRIEDRICH, J. ZUSTIN, A.M. LUEBKE, T. ROSENBAUM, M. GOSAU, C. HAGEL, F.K. KOHLRUSCH, I. WIELAND, M. ZENKER (Hamburg; Regensburg; Duisburg; Magdeburg, Germany) .................................................................................................................. 1711

Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study. T. TAMURA, K. KAWAKADO, G. MAKIMOTO, M. NAKANISHI, S. KUYAMA (Iwakuni, Japan) .................................................................................................................. 1737

Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab. H. TACHIBANA, Y. ISHIYAMA, M. YOSHINO, K. YAMASHITA, D. TOKI, T. KONDO (Tokyo, Japan) .................................................................................................................. 1743


Association Between Serum Alamin Levels and Disease-specific Indices in Patients With Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. S.S. AHN, T. YOON, J.J. SONG, Y.-B. PARK, S.-W. LEE (Seoul, Republic of Korea) .................................................................................................................. 1761


Granulocyte Colony-stimulating Factor Producing Oropharyngeal Squamous Cell Carcinoma. G. SCHURMANN, M. ZWEIFEL, R. GIGER, T.T. RAU, S. VINZENS, M.S. DETTMER, Y. KURIAN (Biel-Bienne; Bern; Thun, Switzerland) .................................................................................................................. 1785

Association of Psychometric Indices and Normal Electrodiagnostic Studies in Referral for Suspected Carpal Tunnel Syndrome. M. PAPADOPOLOU, G. TSIVGOULIS, I. CHATZI, L. PALAIODIMOU, M. BREGIANIN, K. VOUMVOURAKIS, I. MICHOPOULOS (Athens, Greece) .................................................................................................................. 1791

Retrospective Study of the Effects of Post-nasal Drip Symptoms on Cough Duration. T. NAKAJIMA, T. NAGANO, Y. NISHIMURA (Kobe, Japan) .................................................................................................................. 1799

Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer. B. HAINOSLADA, A. ZGURA, C. DIACONU, C. MEHEDINTU, X. BACINSCHI, R.M. ANGHEL (Bucharest, Romania) .................................................................................................................. 1803
Impact of K-Ras Over-expression in Laryngeal Squamous Cell Carcinoma. V. PANENIKOLAOU, A. CHRYSOVERGIS, S. MASTRONIKOLIS, E. TSIAMAS, V. RAGOS, D. PESCHOS, D. SPYROPOULOU, P. PANTOS, A. NIOTIS, N. MASTRONIKOLIS, E. KYRODIMOS (Athens; Heraklion; Ioannina; Patras, Greece) ................................................................. 1611

Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients. M. RIGHINI, V. DALMASTRI, I. CAPELLI, C. ORSI, G. DONATI, M.G. PALLOTTI, C. PEDONE, G. CASELLA, P. CHIECO, G. LA MANNA (Bologna, Italy) .................................................................................................................. 1617

Leukocyte Esterase and Glucose Reagent Test Can Rule in and Rule out Septic Arthritis. L. KOLBECK, M. HAERTLE, T. GRAULICH, M. ETTINGER, E.M. SUERO, C. KRETTEK, M. OMAR (Hannover; Munich, Germany) ........................................................................................................... 1625

Ultrasound Echogenicity of Papillary Thyroid Cancer Is Affected by Tumor Growth Patterns and Tumor Fibrosis. Y.-S. LIM, Y.S. LEE, J.-C. LEE, S.-M. SON, D.-H. SHIN, S.S. KIM, I.-J. KIM, B.-J. LEE (Goyang; Seoul; Yangsan; Busan, Republic of Korea) .............................................................................. 1633

Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml. H. MASUDA, K. MIKAMI, K. OTSUKA, K. HOU, T. SUYAMA, K. ARAKI, S. KOJIMA, Y. NAYA (Chiba, Japan) ................................................................. 1641

Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib. Y. SHIMAMURA, K. ABE, T. MAEDA, T. MATSUI, A. ISHIGURO, H. TAKIZAWA (Sapporo, Japan) ........................................................................................................................ 1647


Myocardial Fibrosis as a Predictor of Ventricular Arrhythmias in Patients With Non-ischemic Cardiomyopathy. C. SCHIAU, D.-C. LEUCUȚA, S.M. DUDEA, S. MANOLE (Cluj-Napoca, Romania) .......................................................................................................................... 1677


Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer. J. HARADA, Y. MIYATA, K. ARAKI, T. MATSUDA, Y. NAGASHIMA, Y. MUKAE, K. MISTUNARI, T. MATSuo, K. OHBA, Y. MOCHIZUKI, H. SAKAI (Nagasaki, Japan) ................................................................................................................ 1693

3'UTR-CDKN2A and CDK4 Germ line Variants Are Associated With Susceptibility to Cutaneous Melanoma. D. TOVAR-PARRA, S.R. GIL-QUIÑONES, J. NOVA, L.D. GUTIÉRREZ-CASTAÑEDA (Bogotá, Colombia) ........................................................................................................... 1529

The Effect of Lutein on Ischemia-reperfusion-induced Vasculitic Neuropathic Pain and Neuropathy in Rats. S. YUCELI, G.N. YAZICI, R. MAMMADOV, H. SULEYMAN, S. OZDOGAN (Erzincan; Istanbul, Turkey) ................................................................................................................................................... 1537

Analyzing the Expression of Biomarkers in Prostate Cancer Cell Lines. C.-Y. SU, G.-C. HUANG, Y.-C. CHANG, Y.-J. CHEN, H.-W. FANG (Taipei; Zhunan, Taiwan, ROC) ................................................................. 1545


Higher Branched-chain Amino Acids and Lower Serine Exist in the Plasma of Nondiabetic Mice: A Comparison Between High- and Low-protein Diet Conditions. E. ARIMURA, M. USHIKAI, M. HORIUCHI (Kagoshima, Japan) .............................................................................................................................. 1555

Clinical Studies

Repeated 5-aminolevulinic Acid Instillations During Follow-up in Non-muscle-invasive Bladder Cancer: A Randomized Study. E. KELLONIEMI, R. JÄRVINEN, P. HELLSTRÖM, E. RINTALA, S. AALTMANAA, T. ISOTALO, K. INNOS, E. KAASINEN (Helsinki; Oulu; Kuopio; Lahti; Hyvinkää, Finland) ........................................................................................................................................................................... 1561

Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery. C. NIEDER, B. MANNSÅKER, R. YOBUTA (Bodø; Tromsø, Norway) ........................................................................................................................................................................... 1569


Eyeglasses Reduce Risk of COVID-19 Infection. S. LEHRER, P. RHEinstein (New York City, NY; Severna Park, MD, USA) ........................................................................................................................................................................... 1581

Phenotype and Surgical Treatment in a Case of Proteus Syndrome With Craniofacial and Oral Findings. R.E. FRIEDRICH (Hamburg, Germany) ........................................................................................................................................................................... 1583

Associations Between Time to Treatment Start and Survival in Patients With Lung Cancer. T. STOKSTAD, S. SØRHAUG, T. AMUNDESEN, B.H. GRØNBERG (Trondheim, Norway) ........................................................................................................................................................................... 1595

Physiology and Pathology of Contractility of the Myometrium. A. KOUTRAS, Z. FASOULAKIS, A. SYLLAIOS, N. GARMPI, M. DIAKOSAVAS, A. PAGKALOS, T. NTOUNIS, E.N. KONTOMANOLIS (Athens; Xanthi; Alexandroupolis, Greece) .......................................................... 1401

Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence. I. SUZAKI, H. KOBAYASHI (Tokyo, Japan) .................................................................................................................. 1409


Experimental Studies

Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer. S. PENG, W. DONG, Q. CHU, J. MENG, H. YANG, Y. DU, Y. SUN, R.M. HOFFMAN (Hefei, P.R. China; San Diego, CA, USA) ............................ 1437

Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells. A. NAKAYAMA, H. IDE, Y. LU, A. TAKEI, K. FUKUDA, A. OSAKA, G. ARAI, S. HORIE, H. OKADA, K. SAITO (Saitama; Tokyo, Japan) .................................................................................................................. 1443

Anti-asthma Drugs Formoterol and Budesonide (Symbicort) Induce Orofacial Clefts, Gastrochisis and Heart Septum Defects in an In Vivo Model. M. PETERKA, L. HUBICKOVA HERINGOVA, A. SUKOP, R. PETERKOVA (Prague, Czech Republic) .................................................................................. 1451


Endosialin (CD248) Expression in Fibromas and Soft-tissue Fibrosarcomas in Dogs. M. MARZEC, M. KANDEFER-GOLA, I. JANUS, J. BUBAK, M. NOWAK (Wroclaw, Poland) .................................................................................................................. 1467


Bone Micromorphology and Material Attrition After Sonic, Ultrasonic and Conventional Osteotomies. A. RASHAD, S. SCHWAN, A. NASIRPOUR, I. SCHMITZ, H. HANKEN, R.E. FRIEDRICH, M. GOSAU (Aachen; Hamburg; Halle (Saale); Bochum, Germany; Tehran, Iran) .................................................................................................................. 1499

Depletion of NK Cells Resistant to Ionizing Radiation Increases Mutations in Mice After Whole-body Irradiation. H.-R. PARK, U. JUNG (Jeongeup; Daejeon, Republic of Korea) .................................................................................................................. 1507